Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2001-06-19
Share capital
329,944,036.00 PLN
Activity description

Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - is a Polish manufacturer of pharmaceuticals, dietary supplements, and products for both pharmacy and non-pharmacy markets. Their brands include IBUM, DIH, Ulgix, and NaturKaps, and they have been committed to high-quality pharmaceutical products since the 1980s.

Registered address
Żmigrodzka 242E, 51-131 Wrocław, Poland
Branches
  • ul. Kwiatkowskiego 9, 55-011 Siechnice
  • Aleje Jerozolimskie 154, 02-326 Warszawa
Email
Phone
Social media
Electronic delivery address
AE:PL-24305-86988-WURJG-23

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$2,357,230

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 83 days late). All were audited by a statutory auditor.

  • 202503/07/2026
  • 202426/06/2025
  • 202325/06/2024
  • 202229/06/2023
  • 202106/10/2022
  • 202025/06/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Sector · Manufacturing624 / 24,548
Top 2.5%
City · Wrocław71 / 13,650
Top <1%
Voivodeship · Dolnośląskie149 / 23,831
Top <1%
Country · Poland1,909 / 297,069
Top <1%

Results vs industry

Revenue
This companyUSD 119.62mMedianUSD 913.43kAverageUSD 25.82m
Net profit
This companyUSD 5.00mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 107.03mMedianUSD 846.99kAverageUSD 21.42m
Assets
This companyUSD 147.08mMedianUSD 897.46kAverageUSD 31.52m

Websites

The company has 6 websites. All of them run on WordPress.

  • hasco-lek.plInspiruje nas Twoje zdrowie i komfort życia | Hasco-Lek
    WordPress 7.1ElementorYoast SEOWPMLLiteSpeed
  • hascovircontrol.plHascovir® – pozbądź się opryszczki z Hascovir control MAX
    WordPress 7.1ElementorYoast SEOLiteSpeed
  • melnabol.plMel na ból - lek przeciwbólowy i przeciwzapalny
    WordPress 7.1ElementorYoast SEOLiteSpeed

Trademarks

The company currently holds no active trademarks with the Polish Patent Office. 44 marks have expired or were not registered. The first mark was filed in 1995.

MarkNumberClassesStatusProtected until
Hascoderm lipocontrol (word)Z.3975593, 5Not registered –
Mark without a word element (figurative)Z.3954925Refused –
LORAST (word)Z.3873795, 44Refused –
Ulgix regulacja Z.3805435, 30, 44Proceedings discontinued –
BluMAG jedyny Z.3737445, 29, 44Proceedings discontinued –
MarkProtected until
Hascoderm lipocontrol (word)–
Mark without a word element (figurative)–
LORAST (word)–
Ulgix regulacja –
BluMAG jedyny –

Job offers

The company has its own careers page: hasco-lek.pl/kariera/dlaczego-warto-z-nami-pracowac.

Authorized Representatives

Agnieszka Han age 40 – Vice President of the Management Board
Maciej Edward Podraza age 46 – Vice President of the Management Board
Tomasz Marcin Han age 42 – Vice President of the Management Board

Manner of representation

For submitting declarations of will on behalf of the company and signing documents, each member of the management board is authorized to act independently.

Supervisory board

Małgorzata Aleksandra Han age 70 – Supervisory Board Member
Aleksandra Marta Han-Matuszczak – Supervisory Board Member
Elżbieta Krystyna Sokulska age 75 – Supervisory Board Member

Beneficial owners

Person

Subsidiaries

NameStake
99.9852%
99.9654%
HB Invest sp. z o.o.
33.9691%

Bank accounts

Registered as a VAT taxpayer on 2005-11-01.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Land (incl. perpetual usufruct)
$2.1M
Buildings and premises
$27M

Public aid

21 public aid cases recorded, with a total value of $4,834,430.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
De minimis aid (in accordance with Commission Regulation 2023/2831)
–

European Funds

ProjectEU co-financing
Implementation of process innovation at Przedsiębiorstwo Produkcji Farmaceutycznej Hasco-Lek S.A. in the form of computer-assisted interpretation of analytical and process data to define the design space during R&D work on new products, through the purchase of specialist equipment and software
$282.8K

Regulatory authorisations

AuthorityTypeStatus
Waste generation Active

Competitors

Name
Adamed Pharma S.A.
Biofarm sp. z o.o.
Zentiva Polska sp. z o.o.
Olimp Laboratories sp. z o.o.
Farmak International sp. z o.o.
Synoptis Pharma sp. z o.o.
Polfarmex S.A.
Zakłady Farmaceutyczne Colfarm S.A.
Exim Pharma sp. z o.o.
Aristo Pharma sp. z o.o.

Change history

DateEvent
2026-10-08PKD change
2004-03-30Share capital increase
2003-10-28Name change
2002-05-14Share capital increase
2001-09-21Address change

FAQ

Last updated: 2026-10-08